FOLH1 and neoplasm: The therapeutic efficacy of 225Ac-PSMA-617 targeted alpha therapy (TAT) by Kratochwil et al.11 demonstrated sustained tumor-control in those patients, who have progressed despite standard therapeutic options and 177Lu-PSMA-RLT.